Articles

Join the Health Care Revolution



American Associated Pharmacies (AAP) invites independent pharmacies to join the RxAlly network. This alliance of more than 20,000 pharmacies is the largest Performance Network of aligned pharmacies in the country. RxAlly was developed to provide a new solution to the critical issues of providing additional access to care and ensuring effective health care spending at a time when prescription medicine misuse is associated with $290 billion in annual costs. The RxAlly network of pharmacies aims to improve patient health through enhanced pharmacist care that combines clinical services and a common technology platform.

Who is in the network and who can join?

This new network is made up of independent pharmacies, regional chains and Walgreens. Independent pharmacies are able to apply for participation in the RxAlly network through a participating independent pharmacy organization (IPO).

Why should I enroll through AAP?

AAP is one of largest independent pharmacy cooperatives in America serving exclusively independent pharmacies and has the capacity to welcome new pharmacy members immediately. AAP is more than just a pharmacy buying group, offering a member owned warehouse, member owned third party contracting, and many other ancillary programs. Independent pharmacies enrolling in RxAlly through AAP will have the opportunity to take advantage of these programs as well.

Jon Copeland R.Ph., C.E.O of AAP, states "We are actively investing our time, resources and talents in the development of RxAlly. This is a collaborative effort to better serve our members patients and improve the delivery of healthcare, the likes of which the United States has not seen to date." RxAlly's network will equip independent pharmacies to bring together the best of personalized care with innovative new technologies, products and services.

Pharmacies interested in joining RxAlly through AAP are encouraged to call
1-877-797-9227 or by visiting www.rxaap.com for more info.

Information from Merck

P.O. Box 1000
North Wales, PA 19454-1099

Product Available

JANUMET® XR (sitagliptin and metformin HCl extended-release) tablets

February 2012

Dear Pharmacist:

Merck is pleased to announce the availability / pricing of JANUMET XR.

JANUMET XR is available as 50-mg/500-mg, light blue, film-coated tablets with "78" debossed on one side, 50-mg/1000-mg, light green, film-coated tablets with "80" debossed on one side, and 100-mg/1000-mg blue, film-coated tablets with "81" debossed on one side.

JANUMET XR will be delivered in bottles featuring a new label design. Approved by the US Food and Drug Administration on June 10, 2011, the label changes are a result of comprehensive research conducted directly with pharmacists and pharmacy technicians.

How Supplied Packaging NDC Number Direct Price
JANUMET XR 50-mg/500-mg tablets 60-count unit-of-use trade package 0006-0078-61 $213.15
JANUMET XR 50-mg/500-mg tablets 180-count unit-of-use trade package 0006-0078-62 $639.41
JANUMET XR 50-mg/500-mg tablets 1000-count bulk package 0006-0078-82 $3,552.28
JANUMET XR 50-mg/1000-mg tablets 60-count unit-of-use trade package 0006-0080-61 $213.15
JANUMET XR 50-mg/1000-mg tablets 180-count unit-of-use trade package 0006-0080-62 $639.41
JANUMET XR 50-mg/1000-mg tablets 1000-count bulk package 0006-0080-82 $3,552.28
JANUMET XR 100-mg/1000-mg tablets 30-count unit-of-use trade package 0006-0081-31 $213.15
JANUMET XR 100-mg/1000-mg tablets 90-count unit-of-use trade package 0006-0081-54 $639.41
JANUMET XR 100-mg/1000-mg tablets 1000-count bulk package 0006-0081-82 $7,104.58

A Fact Sheet is enclosed to provide details on the trade package for JANUMET XR.

At Merck, patient safety is our highest priority, and Merck is committed to ensuring that patients receive appropriate information concerning the benefits and risks associated with therapy involving JANUMET XR. To obtain copies of the Medication Guide for your patients, please call 866-908-6585 (toll-free, 8:00 AM to 8:00 PM ET). Copies of the Medication Guide will be provided to you at no cost. You may also print copies directly from JanumetXR.com.

If you have any questions regarding JANUMET XR, please contact the Merck National Service Center at 800-672-6372 or your Merck National Account Director.

Sincerely,

Rose Mary B. Hoy, R.Ph.
Executive Director, Pharmacy & Distribution

Copyright © 2012 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
All rights reserved. DIAB-1027297-0000 02/12

Formulary Wins For NovoLog and NovoLog Mix 70/30


Thank you for all you do!

Thank you for all you do!

A product reminder from Eli Lilly and Company

Indication for Humalog
bullet.gif

Humalog® (100 units/mL) is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

Select Safety Information for Humalog
bullet.gif

Humalog is contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to Humalog or any of its excipients.
bullet.gif

Closely monitor blood glucose in all patients treated with insulin. Change insulin regimens cautiously.
bullet.gif

Humalog should be given within 15 minutes before or immediately after a meal.
bullet.gif

Hypoglycemia is the most common adverse effect of Humalog therapy. The risk of hypoglycemia increases with tighter glycemic control. Severe hypoglycemia may be life threatening and can cause seizures or death.
bullet.gif

Humalog has not been studied in children with type 1 diabetes less than 3 years of age or in children with type 2 diabetes.

Please click the links at the top of the page to access Patient Information and Full Prescribing Information for Humalog.

Please see full user manual that accompanies the pen.

Dear Healthcare Professional:

Humalog is still readily available in 3 mL cartridges for use by your patients with diabetes. The Humalog cartridge is approved for use in HumaPen® LUXURA™ HD, a reusable pen that delivers an accurate dose of Humalog in 0.5-unit increments.

Available in packs of 5 (NDC 0002-7516-59), the 3 mL cartridges can be ordered through the normal ordering process from any of the Lilly Authorized Distributors shown below. Authorized distributors are also listed at www.LillyTradeRelationsAnswers.com.

The 3 mL cartridges and HumaPen LUXURA HD are part of a portfolio of Humalog products and delivery devices designed to provide treatment options for you and your patients with diabetes.

Wholesaler/Distributor

Product Order
Entry Number

AmerisourceBergen

855-551

Bellco

774-034

Burlington Drug

355404

Cardinal Health

2982510

Dakota Drug Inc.

181040

Dik Drug Company

938555

Frank W. Kerr Co.

27748

H.D. Smith Wholesale Drug Co.

114-9343

Kinray, Inc.

617936
 

Wholesaler/Distributor

Product Order
Entry Number

McKesson Corporation

1379528

Miami-Luken Inc.

085-829

Morris & Dickson Company Ltd./
Allen Dickson

367383

N.C. Mutual Drug Co.

208611

Prescription Supply Inc.

281659

Rochester Drug Company

16111700

Smith Drug Company

321414

Valley Wholesale Drug

604769

Value Wholesale Drug Company

257584

For more information, please visit Humalog.com or contact Eli Lilly and Company
at 1-800-LillyRx (1-800-545-5979).

Sincerely,

Lilly USA, LLC

Important Safety Information for Humalog

Contraindications
bullet.gif

Humalog® is contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to Humalog or any of its excipients.

Warnings and Precautions
bullet.gif

Dose Adjustment and Monitoring: Closely monitor blood glucose in all patients treated with insulin. Change insulin regimens cautiously. Concomitant oral antidiabetic treatment may need to be adjusted.

The time course of action for Humalog may vary in different individuals or at different times in the same individual and is dependent on many conditions, including delivery site, local blood supply, or local temperature. Patients who change their level of physical activity or meal plan may require insulin dose adjustment.
bullet.gif

Hypoglycemia: Hypoglycemia is the most common adverse effect of Humalog. The risk of hypoglycemia increases with tighter glycemic control. Educate patients to recognize and manage hypoglycemia. Hypoglycemia can happen suddenly and symptoms may vary for each person and may change over time. Early warning symptoms of hypoglycemia may be different or less pronounced under conditions such as long-standing diabetes, diabetic nerve disease, use of medications such as beta-blockers, or intensified diabetes control. These situations may result in severe hypoglycemia and possibly loss of consciousness prior to the patient’s awareness of hypoglycemia. Severe hypoglycemia may be life threatening and can cause seizures or death.

Use caution in patients with hypoglycemia unawareness and who may be predisposed to hypoglycemia. The patient’s ability to concentrate and react may be impaired as a result of hypoglycemia. Rapid changes in serum glucose levels may induce symptoms similar to hypoglycemia in persons with diabetes, regardless of the glucose value.

Timing of hypoglycemia usually reflects the time-action profile of administered insulins. Other factors such as changes in food intake, injection site, exercise, and concomitant medications may alter the risk of hypoglycemia.
bullet.gif

Allergic Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with Humalog.
bullet.gif

Hypokalemia: Humalog can cause hypokalemia, which, if untreated, may result in respiratory paralysis, ventricular arrhythmia, and death. Use caution in patients who may be at risk for hypokalemia (eg, patients using potassium-lowering medications or medications sensitive to serum potassium concentrations).
bullet.gif

Renal or Hepatic Impairment: Frequent glucose monitoring and insulin dose reduction may be required in patients with renal or hepatic impairment.
bullet.gif

Mixing of Insulins: Humalog for subcutaneous injection should not be mixed with insulins other than NPH insulin. If Humalog is mixed with NPH insulin, Humalog should be drawn into the syringe first. Injection should occur immediately after mixing.

bullet.gif

Subcutaneous Insulin Infusion Pump: Humalog should not be diluted or mixed when used in an external insulin pump. Change Humalog in the reservoir at least every 7 days. Change the infusion set and insertion site at least every 3 days.

Malfunction of the insulin pump or infusion set or insulin degradation can rapidly lead to hyperglycemia and ketosis. Prompt correction of the cause of hyperglycemia or ketosis is necessary. Interim subcutaneous injections with Humalog may be required. Train patients using an insulin pump to administer insulin by injection and to have alternate insulin therapy available in case of pump failure.
bullet.gif

Drug Interactions: Some medications may alter glucose metabolism, insulin requirements, and the risk for hypoglycemia or hyperglycemia. Signs of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs. Particularly close monitoring may be required.

Adverse Reactions
bullet.gif

Adverse reactions associated with Humalog include hypoglycemia, hypokalemia, allergic reactions, injection-site reactions, lipodystrophy, pruritus, rash, weight gain, and peripheral edema.

Use in Specific Populations
bullet.gif

Pediatrics: Humalog has not been studied in children with type 1 diabetes less than 3 years of age or in children with type 2 diabetes.

Dosage and Administration
bullet.gif

Humalog should be given within 15 minutes before or immediately after a meal.

Please click the links at the top of the page to access Patient Information and Full Prescribing Information for Humalog.

Please see full user manual that accompanies the pen.

HI HCP ISI 08JUN2011

Humalog® is a registered trademark of Eli Lilly and Company and is available by prescription only.
HumaPen® LUXURA™ is a registered trademark of Eli Lilly and Company. HumaPen® LUXURA™ HD is available by prescription only.

HI73445     0911     ©Lilly USA, LLC 2011. All rights reserved.

Subcategories